Gateway Bio is developing an innovative “PEG-like” drug conjugation technology that eliminates the antigenicity issues surrounding PEGylation today. Gateway Bio was specifically formed to translate several scientific breakthroughs from the lab of Professor Chilkoti at Duke University into commercially viable products and processes by combining the expertise of the academic scientists closest to these technologies with the business acumen of experienced start-up professionals. The initial core technology of Gateway Bio is based on several key patents on POEGMA conjugates that have been successfully licensed from Duke by Gateway Bio. Our novel method of creating PEG-like conjugates could be applied to generics, existing drugs, newly developed drugs or any of the PEGylated pharmaceuticals currently on the market. There are currently 15 FDA-approved peglyated drugs, with dozens more in clinical trials. Sales of the two most successful pegylated products, Pegasys and Neulasta, exceeded $5 billion in 2011.
Stenting is frequently used in Peripheral Artery Disease (PAD) to treat the symptoms of Atherosclerosis. However, this treatment has risks, including restenosis 60% of the time and late thrombosis that result in high re-intervention rates, non-healing ulcers, and higher risk for amputation. NuStent is developing an imageable, magnetic biodegradable intravascular scaffold as a new alternative to classical stents for PAD. In vivo porcine studies demonstrated safety and feasibility for deployment.
This device allows for damage free handling of sensitive devices and surfaces, and for applications that involve quick attach and release of surfaces. The total market opportunity for this company is approximately 36 billion. Conventional techniques to grab surfaces use a vacuum/suction strategy but these suffer an intrinsic limit of adhesion strength—1 atm (approximately 100 kPa) and are bulky. The switchable adhesion device is an electro-osmotic pump that uses individually-controlled oscillating water droplets to easily, carefully and quickly pick and place tiles in parallel.
Fungal infections can be painful and deadly, and immunocompromised patients (e.g., HIV/AIDS, cancer) have high infection risk. There are no safe and specific treatments to prevent infections in these high-risk patients and infection is largely due to 'good' microbes turning 'bad'. AVnovum is developing novel peptides for preventing fungal infections in these immunocompromised patients. AVnovum is actively seeking development partners and seed funding to pursue pre-clinical testing and IND-enabling studies.
Although electronic pacemakers are the current treatment for symptomatic atrioventricular block or sinoatrial node dysfunction, the maintenance they require and the risk of complications have motivated research on biological alternatives. Rhythm Therapeutics initial product, the biological pacemaker, assists in the depolarization and subsequent action potentials required for a proper heartbeat. It utilizes adeno associated virus (AAV) vectors to deliver ion channel genes into heart tissue, resulting in over-expression of these ion channels, and correction of the beating rate of individuals with bradycardia.
Currently there are several solutions under consideration for disinfecting N95 respirators for re-use, with UV-C as the preferred solution because of ease of deployment and widespread applicability. Problematically, present UV-C disinfection solutions are limited by shadowing, which prevents exposure of the masks to the required effective dose of UV irradiation. The inventors utilized UV-C light field modeling and extensive test measurements to develop a proprietary arrangement of lamps for disinfecting. The configuration eliminates shadowing, allowing for full irradiation and disinfecting of the contaminated N95 respirator surface in the shortest amount of time.
Natural product molecules (and derivatives) are important for the development of modern drugs, as they play a vital role in the pipeline for new therapeutics. For example, >100 FDA-approved drugs are derived from tetracyclic terpenoids, which can be metabolized by the body into steroids. Despite this success, there remain considerable limitations to broad medicinal exploitation of the class due to lingering scientific challenges associated with compound availability. Carbacyclix has developed a concise asymmetric route to forging natural and unnatural (enantiomeric) C19 and C20 tetracyclic terpenoid skeletons suitable to drive medicinal exploration. While efforts have been focused on establishing the chemical science, early investigations reveal that the emerging chemical technology can deliver compositions of matter that are potent and selective agonists of the estrogen receptor beta.
Inferior vena cava (IVC) filters are implantable devices that prevent clots from embolizing from the legs to the lungs. Even though the FDA recommends retrieval of the filter when the risk of VTE or bleeding has resolved, IVC filter removal is technically challenging and sometimes impossible because of tilt and scarring. The team has developed and patented a device that can safely retrieve filters in any configuration.
Foot Drop is a mobility disorder prevalent in patients that is a common result of neurological injuries or diseases such as stroke cerebral palsy, MS or brain tumors. Foot drop is characterized by the inability to lift the toes toward the shin. It inhibits the rhythmic swing phase of the gait, increasing the probability of falls and manifests in abnormal gait patters that inhibit mobility and create imbalances and stress. Currently, there is not a rehabilitative solution that is cost effective and practical for every day independent use. Dr. Tyler Susko has developed a shoe that provides a low-friction out-sole during the swing phase of the gait, and a high-friction out-sole during the stance phase of the gait. The design can be used on any style shoe. Preliminary pilot studies with impaired adults have shown immediate gait improvement.
Current point of care diagnostics frequently require blood draws (e.g., blood glucose monitoring for diabetes), hampering our ability to continuously monitor biomarkers such as cortisol and electrolyte levels. Understanding these levels are critical for a range of populations (high-performance athletes, military personnel, the chronically ill). Today, these biomarker analytes can be isolated from sweat with a new platform from FESSwise. The FESSwise platform is capable of broad biomarker monitoring and is pursuing cortisol detection as a first indication. The Freestanding Electrochemical Sensing System (FESS) platform features sweat sampling, electrochemical sensing, and data display / transmission, all within a self-contained wearable platform. The FESS-enabled smartwatch can be used to monitor the metabolite profiles of individuals in sedentary and high-intensity exercise settings.
Articulated Wearables to enhance human productivity. 3rd Arm is prototyping a wearable, articulated robotic device that can be attached to a person at the hip or other location to augment human task productivity. This mechanical "third arm" has many uses such as assisting abled users (e.g. holding additional tools to enhance work), helping disabled users (e.g. providing support and lifting objects), and as a haptic interface for interaction with robotics systems and AR/VR experiences. 3rd Arm is incorporating the latest robotic technology with a newly designed 4-state brake mechanism in joints for advanced operations.
Cancer patients, after the first diagnosis often ask, “how bad is my tumor and what should I do if it is bad?” In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die. Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy. Episteme invented a novel microarray-based platform technology called “ATAC-Array”. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – the only microarray that reads chromatin accessibility. No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary. Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy for better outcome and better quality of life.
Artificial Intelligent Medical Imaging: Safer, Faster, Cheaper Medical Imaging Enabled by AI and Deep Learning. The clinical challenges in radiology frequently highlighted are the large radiation doses, long imaging times, expensive hybrid imaging equipment, and expensive room shielding. AI-MI combined with SPECT (Single Photon Emission Computed Tomography) aims to provide equivalent diagnostic accuracy without CT, at lower doses, at lower cost, and faster - allowing for higher throughput through radiology.
Tendo Technologies, founded in 2017, is a spin-off from the Marcus Hultmark research lab at Princeton developing a novel flow sensing/measurement technology. This unique technology achieves extreme sensitivity (for both gases and liquids) through the nanoscale conductive ribbons that will deflect when placed in flow. The nanoribbons are manufactured with standard semiconductor-based techniques, resulting in high scalability and low unit cost for the sensing chip. As a highly versatile technology (flow measurement is ubiquitous), Tendo envisions that their tech can be applied in many industries for various applications, when equipped with appropriate "wrappers" around it. For example, the Tendo chip plus communication package would be appropriate for IoT applications such as real time air measurement in HVAC ducts; alternatively, more sophisticated housing with control would bring benefits for flow metering and control during industry manufacturing processes.
90% of cancer-related deaths occur due to metastasis. While effective therapies exist to treat primary tumors, treatments to slow/stop metastasis remain ineffective. While immuno-oncology is a new avenue for fighting these metastasized tumors, priming the immune cells has proven difficult. Here, the lab of Prof. King demonstrates a new method to functionalize immune cells. This technology can be applied to metastatic forms of prostate (1.1 million men diagnosed in 2012) and colorectal cancer (1.2 million cases diagnosed in 2015.)
VaxNewMo’s goal is to be the next bioconjugate vaccine platform company. It is seeking a business co-founder to help shape a clinical development, fundraising, and partnership strategy that can maximize its impact and value
Sense4me is developing a digital platform that predicts relapse in patients with alcohol use disorder. Through wearable sensors, sense4me provides real-time measurements of a patient’s sympathetic nervous system and hypothalamus, data that can act as an alert to subdue cravings before they cause the patient to relapse. This just-in-time intervention powered by personalized health analytics has the potential to reduce relapse rates, which can be as high as 80-95% among patients in their first year of treatment for alcohol and nicotine addiction. Dysregulation of the stress system has been associated with a shorter time to future relapse in alcoholics. By monitoring stress responses, this technology empowers the 14.8M Americans with alcohol use disorder to actively participate in their treatment and take control of their cravings. A collaboration between Columbia’s Dr. Lili Deligianni and Dr. Nasir Naqvi, sense4me is seeking $500K in seed funding to complete a wearable prototype and accompanying software.
The current standard for distinguishing between benign and cancerous skin legions require an invasive skin biopsy followed by a waiting period for lab results for diagnosis. OptoVibronix is eliminating the need for invasive skin biopses to diagnose a skin legion as cancerous or benign. The technology scans the skin legion and results in a diagnosis in just 15 minutes. By avoiding skin biospy, it improves the patient experience and efficiency of diagnosis and reduces healthcare costs.
A Novel Platform to Develop piRNA-Based Therapeutics for Cancer Treatment. PIWI-interacting RNAs (piRNAs) is a novel pathway for nucleic acid based targeted therapy. piRNAs consist of small non-coding RNAs that interact with PIWI proteins. The PIWI/piRNA pathway protects the genome from destabilizing transposon activity by using piRNA to guide PIWI proteins to transposable genome sites, leading to gene specific methylation in somatic cells. piRNAs offer potential advantages because the longer piRNA seed sequences results in higher target specificity, higher tissue specificity, higher efficacy, and lower toxicity over siRNA and miRNA techniques. Short-term focus is currently on treating liver cancer because of the relative ease of drug delivery and lack of effective treatments.
Northwestern researchers have devised a new formula for black hair dye using graphene. Leveraging graphene’s high surface area, flexibility, electrical and thermal conductivity, the inventors have developed a multi-functional hair dye that can be used to control the lightness/darkness of hair. The graphene dye is both robust (able to stay on even after 30 washes) and non-toxic (minimal to no hair damage was observed after wash-out). This technology has received considerable attention in the popular press, including the NY Times, BBC, NPR, Fast Company, Refinery29, and other news outlets.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults. IPF is a fatal disease with median survival at 3-5 years. While there exist several clinical approaches to treating IPF, few therapeutics have been clinically proven to provide significant benefits to patients. Eleven P15 is uniquely positioned for early detection and early intervention of IPF. The pivotal discovery of a common polymorphism in the promoter of MUC5B (rs35705950) has been associated with IPF and pulmonary fibrosis associated with rheumatoid arthritis, and this polymorphism increases the production of mucus.
Cognivive develops FDA-registered, personalized, evidence-based, prescription digital therapeutics used by patients at home to treat neuromotor and neurocognitive impairments resulting from stroke.
Dermal fillers are implantable medical devices injected into the skin to help fill in facial wrinkles, restoring a smoother appearance. In 2018, there were >2,600,000 dermal filling procedures performed in the US, and the market was estimated to reach $10 billion by 2023. Despite the high demand, no dermal filler has been approved by FDA for injection in the superior portion of the face. High blood vessel density around the eye presents the risk for vascular occlusion leading to skin necrosis or blindness. UCLA researchers led by Prof. Timothy Deming and Michael Delong reported a novel dermal filler material, polyion-complex deblock copolypeptide hydrogels (PIC-DCH), which is safer than the currently used hyaluronic acid.
Ear infections are the number on cause of doctors visits worldwide, affecting 700 million people each year. Chronic ear infections are often treated with the insertion of a tympanostomy tube into the ear drum. While these help to drain fluid, they often come with complications which can result in follow up surgeries and hearing loss. The PionEar tympanostomy tube technology addresses the most common complications by changing the geometry and materials of the tube to enhance fluid transport and reduce the chances of biofilm formation.
The Tissue Oracle addresses an unmet need to identify which regions of excised breast tissue should undergo histopathological assessment to diagnose breast disease. Our envisioned product deploys optical coherence tomography (OCT) imaging and artificial intelligence image analysis to achieve the microscopic-level resolution, large field of view, and fast throughput necessary for integration into clinical workflow. The value proposition is that our image-guided sample selection can reduce the number of tissue blocks submitted for histopathology, and the associated cost and workload, by 30-50%. The target customers are pathologists and administrators seeking greater efficiency for a key step in breast cancer care.
Loss of brain synapses is highly correlated with symptom progression in Alzheimer’s dementia, but there is currently no treatment to slow or halt synapse loss. Allyx’s prion protein antagonists rescue synapses and memory function by interrupting the deleterious signaling triggered by amyloid without removing plaque itself and are effective at reversing deficits after they develop.
Many diseases can only be diagnosed properly by looking at sections of the tissue post-mortem or from invasive biopsies. Imaging of subtle textural aspects of tissue is not possible due to low resolution in magnetic resonance (MR) images. bioProtonics has developed a method to measure tissue texture using MR data without the need for rendered images. In many diagnostic workflows, the bioProtonics technique could replace biopsies. Such applications include neurodegenerative disease, liver disease, osteoporosis, cancer, lung disease, prostate disease.
Therapeutics for Fatty Acid Oxidation Disorders. EnergXTherapeutics is developing a platform of drug products that provides comprehensive treatment solutions that targets the biochemical defects induced by deficiency of enzymes/proteins that participates in the mitochondrial long chain fatty acid oxidation (FAO) pathway reactions. Broad IP claims are issued, with more pending, that puts this team in a strong position to utilize its products platform for treating several FAO diseases.
Numerous clinical trials in amyloidosis have failed as a result of misdirected focus on amyloid states of disease-causing proteins. Pangolin Therapeutics’ (PTx) small-molecule platform, termed Pangomers™, was developed to address this deficiency. The Pangomer™ core structure enables selective targeting of pre-amyloid, toxic oligomers (PAOs). Here, we seek to address Multiple System Atrophy (MSA), an aggressive, orphan-indicated form of Parkinson's for which there are no approved therapeutics. Our pilot efforts have identified and validated a strategy for development of Pangomer™ analogues that neutralize PAOs from MSA. Additional funding will allow execution of this strategy delivering a lead molecule for pre-clinical advancement.
AIFEN is developing a two stent, fenestrated aorto-iliac endograft system for repairs in atherosclerotic occlusive diseases. AIFEN is founded by Prof. Mohamed Zayed, the co-founder and CMO of Caeli Vascular. Dr. Zayed is a rising star in fostering innovation at Washington University in St. Louis, with 8 new medtech inventions over the past 3 years. His disclosures have lead to four patent filings and one license to his startup, Caeli.
Inflammatory diseases are often treated with immunomodulatory drugs which can result in severe side effects due to their systemic administration. This technology is a vitamin D analog which can be administered topically, therefore reducing systemic side effects. The drug works by triggering release of a regulatory cytokine from the skin and decreasing T cell activation which is involved in many inflammatory disorders.
SOLUtion Medical is an early-stage life science company developing user-friendly delivery systems for reconstitutable drugs. These devices improve patient outcomes through increased adherence to patient injected life-saving medication. We specifically aim to improve the administration efficacy of life-saving injectable medication with our TwistJect auto-injector for people living with adrenal insufficiency including Addison’s Disease and Congenital Adrenal Hyperplasia.
Nanopath has developed a platform for rapid, point-of-care biomarker purification and characterization from a patient sample. Our technology was originally developed at Dartmouth College as part of our PhD research, and is using advances in bioengineering and nanotechnology to reduce noise and improve signal in diagnostic systems. This allows for an integrated system that takes a complex patient sample, isolates key biomarkers, and analyses them without the need for lengthy clinical workflows. We believe that this new diagnostic paradigm has applications to a range of disease indications including bloodstream infections, cancer liquid biopsy, urinary tract infections, respiratory infections, and wound infections.
MedGyde develops ligand and antibody directed products which bind to antigens specific to various cancer subtypes. MedGyde’s pipeline includes antibodies and single-chain variable fragments which have demonstrated cytotoxic properties. The products have therapeutic as well as diagnostic applications (theranostic). MedGyde has also developed a radio-sensitization technology that targets and sensitizes cancer cells. The lead therapeutic antibody to inducible neoantigen, TIP1, binds specifically to cancer. It has been conjugated to both radiopharmaceuticals and chemotherapy which markedly improved cancer cures in pre-clinical cancer models. The planned clinical trial will be in patients with advanced non-small cell lung cancer. MedGyde has been awarded several NIH small business grants to further develop antibodies and nanoparticle drug delivery systems. Venture capital is needed for GMP manufacturing and IND enabling safety testing.
Glioblastoma multiforme (GBM) is an incurable form of brain cancer with no effective therapy. Unlike other organs, brain has limited immune surveillance because of blood brain barrier and lack of lymphatics drainage. Immunaxis proposes to exploit the meningeal lymphatic vessels to overcome immune barrier to achieve successful treatment of glioblastoma.
Aero Therapeutics is helping physicians in low-resource settings treat neonatal respiratory issues with their sustainable, rugged and affordable devices. Their current device oxygenates, warms, humidifies, and sterilizes air before it is delivered in a single, compact, and mobile enclosure. Developed iteratively in Ethiopia, their final prototype demonstrates comparable performance with commercially available devices at ~1/10th the cost.
The human immune system participates in complex interactions with virtually all other systems in the body. In particular, the B-cell component of the adaptive immune response plays a role in various disease settings, including infectious disease, cancer, autoimmunity, cardiovascular, hematologic, neurologic diseases, and others. In addition, antibodies (a product of B cells) are effectively used in diagnostics, therapy, and prevention. To address these significant challenges with current technologies for B cell characterization and antibody discovery, we recently developed a novel technology that, for a given sample, enables the mapping of antibody sequence to antigen specificity from a single high-throughput experiment for a large number of antigens and B cells at a time.
Inflammatory diseases such as autoimmune uveitis, multiple sclerosis and psoriasis are thought to be driven by over expression of cytokines such as IL-17. Therapeutic approaches to repress expression of pro-inflammatory proteins are promising, but miRNAs which stabilize the targeted mRNA can inhibit this process. This technology uses oligonucleotides to block the target sites of the stabilizing miRNAs, thus leading to decreased stability of the target mRNA. Based on novel insights into the biology of a new class of microRNAs, TargetSite Therapeutics is harnessing the power of a differentiated oligonucleotide therapeutic platform in order to target pro-inflammatory cytokines involved in therapeutic areas of distinct need.
My Gene Counsel has created scalable, digital technology that pairs specific genetic test results with accurate, continuously updating information for clinicians and consumers. By helping patients and doctors become aware of the implications of genetic testing results, My Gene Counsel can help improve patients' lives and avoid unnecessary risky medical procedures.
The Blue Vertical-Cavity Surface-Emitting Laser (BlueVCSEL) is a breakthrough for projection, display technology, & lighting. Overcoming previous obstacles to commercialization, the team has utilized patented techniques to create the world's first stacking-fault-free semi-polar GaN-on-sapphire materials to make Blue VCSELs a commercial reality.
Parkinson's disease (PD) is characterized by uncontrolled tremors and issues with movement and balance. It affects 1-2% of people over 65, costing the US over $35 billion a year. Current treatments for PD, such as L-DOPA and deep brain stimulation (DBS), only treat the motor symptoms but are not able to fix the underlying cause of the deficits: loss of the nigrostriatal pathway. To address this gap in clinical care, the first “tissue engineered nigrostriatal pathway” was developed outside the body and precisely microinjected as a unit to “wire in” and physically replace the missing pathway, “reversing the clock” on the neurodegenerative progression of PD. Preliminary results in animal models show success recreating the pathway which delivers the dopamine signals that are lost in PD patients. Full pitch deck available upon request.
Keren Therapeutics is focusing on pre‐clinical and early clinical development of recently discovered hormone osteocalcin as treatment for sarcopenia, cancer cachexia, and cognitive impairment due to aging. Osteocalcin is a biological construct that can be synthesized on commercial scale and delivered via depot administration. Development of osteocalcin benefited from more than $7 million in grant support. Columbia patented the composition of matter and its utility through 2034 and 2031, for muscular and cognitive impairment indications, respectively. KEREN intends to file an IND within 18 months from funding. Cost of development through completion of first-in-man studies is expected to be $8,200,000. Osteocalcin is addressing blockbuster market with unmet medical need in case of sarcopenia. We anticipate selling KEREN or executing a co‐development agreement with pharma within 6 years from funding. The Company’s value at that time could exceed $50 million, providing investors with 6x ROI.
Pattern Therapeutics is a developing a novel TLR (toll-like receptor) antagonist to treat NASH (non-alcoholic steatohepatitis) and potentially other indications. NASH is the most common liver disease in the United States, with an estimated prevalence of 4-6% and predicted prevalence growth of 15-50% in the next 15 years. A critical finding is that TLRs mediate the Sterile Inflammation (SI) response and exacerbates metabolic stress. The candidate antagonist - PT-7314 - is a novel compound with excellent Phase 1 safety data, and strong in vitro and in vivo efficacy in mouse models of NASH. Pattern Therapeutics is ready for Phase 2 trails and is looking for an entrepreneur to raise funds to file an IND, manufacture the drug for the clinic, and to lead the trial.
Aging can lead to immunodeficiencies in patients with abnormal thymus function. As a consequence, the body is not able to produce enough new (“naïve”) T cells for the immune system to recognize pathogens and cancer cells or the body is suffering from autoimmune response. Cancer immunotherapy drugs generated $41 Billion globally in 2014, at 50% market share of the overall oncology drugs market . The invention details a new method for producing large quantities of diverse, functional, naïve autologous T cells for infusion into patients. The in vivo generated T cells arise from bone marrow stem cells taken from the patient and become genetically compatible immune cells that are tolerant of the patient and any selected transplant donor.
Neuralert offers non-invasive, wearable wristband devices which monitor asymmetric arm movement/weakness, a tell-tale sign of stroke. Neuralert’s proprietary algorithm accurately identifies stroke symptoms and immediately alerts medical staff to assess the patient and begin treatment. Neuralert’s technology can detect stroke in under an hour, which is more than 4 times faster than manual assessment processes currently used.
Transfoam harnesses engineered microorganisms and renewable feedstocks to tackle plastic pollution at the beginning and end of the product lifecycle. Our proprietary bioprocess reduces the operating cost and environmental footprint of PHB manufacturing to overcome limitations currently hindering the industry’s growth. Plastic is at the forefront of our transition to a circular economy. We treat plastic waste as a valuable resource rather than a burden. By using a waste-based feedstock, we can both remove plastic pollution from the environment and provide a safe, accessible alternative. Polyhydroxybutrayte (PHB) is a bio-based polymer with similar properties as many traditional single-use plastics, except it degrades fully in the environment. PHB is both produced and consumed by microorganisms, leaving behind only traces of water and CO2 after use/disposal.
Kawasaki Disease is an illness that causes inflammation (swelling and redness) in blood vessels throughout the body that comprises three phases, the first of which is usually a lasting fever. The condition most often affects kids younger than 5-8 years years old. Catching Kawasaki disease early is key - children can be treated relatively easily if the disease is detected early, however becomes much more dangerous the longer it goes in diagnosed. The first sign of the disease, fever, is unspecific to Kawasaki disease, and by the time later symptoms manifest, much more aggressive intervention needs to be taken. Thus, a diagnostic that can identify Kawasaki Disease is critical to successfully treating the 5,000-20,000 cases that arise each year in the US, and more globally.
Peripheral arterial disease (PAD) is often treated with the placement of unidirectional sheaths into the arteries of patients. These surgeries often require multiple insertion sites, increasing the risk associated with the surgery. This technology is a bidirectional sheath which reduces the number of insertion sites by half, reducing the complications and cost of PAD treatment.
Prof. Bob Datta and his team at Harvard Medical School have discovered a new class of odorant receptors - MS4As - that is structurally distinct from previously known receptors. In fact, data suggests that stimulating MS4A-bearing cells can significantly increase food intake in mice by hijacking innate preference mechanisms. The screening platform developed by Bob Datta has the potential to unlock numerous naturally-occurring ligands to create unique additives for food and/or fragrances. The science of the MS4As represents the first truly new opportunity to develop a new class of compounds with the potential to influence human and animal olfactory perception. Sandeep Robert (Bob) Datta is an Associate Professor of Neurobiology at Harvard and he is an entrepreneurial faculty member who is currently working on a number of start-ups.
Pearl Bio is an early-stage venture pioneering design and production of next-generation therapeutics and biomaterials for medical applications and beyond. Biology is constrained to the 20 natural amino acids, limiting the ability to site-specifically modify therapeutic proteins to improve half-life, tissue targeting, or assembly. In contrast, chemical synthesis of therapeutics enables access to greater functional diversity, but template-directed synthesis is challenging. Pearl Bio unites the precision of biology with the unlimited diversity of chemistry in a transformative platform that produces therapeutics and biomaterials with tunable properties for applications in oncology, immunology, and rare disease.